Trial Profile
A Multiple-Dose, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of LY3050258
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Aug 2018
Price :
$35
*
At a glance
- Drugs LY 3050258 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 23 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Nov 2014 Planned End Date changed from 1 Oct 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov
- 17 Nov 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov